ResMed Inc. (NYSE:RMD) Shares Sold by LGT Capital Partners LTD.

LGT Capital Partners LTD. lessened its position in ResMed Inc. (NYSE:RMD - Free Report) by 2.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 505,836 shares of the medical equipment provider's stock after selling 14,280 shares during the period. ResMed accounts for about 4.4% of LGT Capital Partners LTD.'s portfolio, making the stock its 6th biggest holding. LGT Capital Partners LTD. owned about 0.34% of ResMed worth $115,680,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of RMD. Concurrent Investment Advisors LLC increased its holdings in ResMed by 3.1% in the 3rd quarter. Concurrent Investment Advisors LLC now owns 1,919 shares of the medical equipment provider's stock worth $469,000 after purchasing an additional 57 shares in the last quarter. Graypoint LLC bought a new stake in shares of ResMed in the 3rd quarter valued at about $233,000. Principal Financial Group Inc. grew its position in shares of ResMed by 2.9% in the 3rd quarter. Principal Financial Group Inc. now owns 186,776 shares of the medical equipment provider's stock valued at $45,596,000 after buying an additional 5,284 shares during the last quarter. Capital Performance Advisors LLP bought a new stake in shares of ResMed in the 3rd quarter valued at about $60,000. Finally, Oxbow Advisors LLC grew its position in shares of ResMed by 3.0% in the 3rd quarter. Oxbow Advisors LLC now owns 12,306 shares of the medical equipment provider's stock valued at $3,004,000 after buying an additional 364 shares during the last quarter. Institutional investors and hedge funds own 54.98% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have commented on RMD shares. Stifel Nicolaus reduced their price target on ResMed from $250.00 to $240.00 and set a "hold" rating on the stock in a research report on Wednesday. StockNews.com lowered ResMed from a "buy" rating to a "hold" rating in a research report on Friday. KeyCorp upped their price target on ResMed from $266.00 to $280.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. JPMorgan Chase & Co. upped their price target on ResMed from $270.00 to $286.00 and gave the company an "overweight" rating in a research report on Friday, January 31st. Finally, Citigroup upgraded ResMed from a "neutral" rating to a "buy" rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat, ResMed presently has a consensus rating of "Moderate Buy" and an average target price of $243.82.

Remove Ads

Insider Transactions at ResMed

In other news, CEO Michael J. Farrell sold 8,009 shares of the stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $236.77, for a total value of $1,896,290.93. Following the completion of the sale, the chief executive officer now directly owns 455,472 shares of the company's stock, valued at $107,842,105.44. This represents a 1.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $242.11, for a total value of $484,220.00. Following the completion of the sale, the director now directly owns 77,218 shares of the company's stock, valued at approximately $18,695,249.98. This trade represents a 2.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 21,186 shares of company stock valued at $4,996,646 over the last ninety days. 0.71% of the stock is currently owned by insiders.

ResMed Stock Up 3.3 %

RMD stock opened at $232.40 on Friday. The stock's 50 day simple moving average is $236.70 and its 200 day simple moving average is $239.93. ResMed Inc. has a fifty-two week low of $172.19 and a fifty-two week high of $263.05. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.29 and a current ratio of 3.33. The company has a market cap of $34.13 billion, a P/E ratio of 27.44, a price-to-earnings-growth ratio of 1.53 and a beta of 0.74.

ResMed (NYSE:RMD - Get Free Report) last posted its quarterly earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, topping analysts' consensus estimates of $2.29 by $0.14. ResMed had a return on equity of 26.17% and a net margin of 25.34%. On average, research analysts expect that ResMed Inc. will post 9.47 earnings per share for the current fiscal year.

ResMed Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Investors of record on Thursday, February 13th will be paid a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.91%. The ex-dividend date of this dividend is Thursday, February 13th. ResMed's dividend payout ratio (DPR) is currently 25.03%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.